Epidermal Hyperproliferation With Less Prominent Dermal Inflammation Is the Unique Histopathological Feature of the Refractory Lesions in Psoriasis Treated With Ustekinumab.
Journal
The American Journal of dermatopathology
ISSN: 1533-0311
Titre abrégé: Am J Dermatopathol
Pays: United States
ID NLM: 7911005
Informations de publication
Date de publication:
01 Apr 2022
01 Apr 2022
Historique:
pubmed:
3
11
2021
medline:
22
3
2022
entrez:
2
11
2021
Statut:
ppublish
Résumé
Although ustekinumab (UST) shows excellent efficacy in treating psoriasis, not all patients have a complete clearance rate. The purpose of this study was to investigate the histopathological characteristics of refractory psoriasis lesions in patients with excellent response to UST. Fifty-seven patients with newly diagnosed psoriasis and 66 patients with a 75% reduction in the Psoriasis Area and Severity Index score after UST treatment were included. Computer-aided image analysis was performed to measure the epidermal thickness, horny layer thickness, number of dermal vessels, and dermal inflammatory cell infiltration rate. Parakeratosis was scored using a 4-point scale. These measurements were compared between the refractory lesions of UST-treated patients and the untreated lesions of newly diagnosed patients after the adjustment for confounding factors. The dermal inflammatory cell infiltration rate was significantly lower in the refractory lesions (P = 0.022). Meanwhile, the epidermal thickness, horny layer thickness, grade of parakeratosis, and dermal vessel count did not differ between the groups (P = 0.125, 0.719, 0.542, and 0.758, respectively). Subgroup analyses were performed within the UST-treated group after dividing them into 2 groups according to the number of treatments or treatment response rates. None of these features were significantly different between the subgroups. This study suggests that the reduction of dermal inflammation by UST was not sufficient to ameliorate the epidermal changes and implies the role of the interleukin-23-independent downstream cytokine pathway in causing the refractory lesions among patients who responded well to UST. The continuation of UST treatment might not further improve epidermal alterations.
Identifiants
pubmed: 34726183
doi: 10.1097/DAD.0000000000002094
pii: 00000372-202204000-00006
doi:
Substances chimiques
Dermatologic Agents
0
Ustekinumab
FU77B4U5Z0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
267-271Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Nestle FO, Kaplan DH, Barker J, et al. Psoriasis. N Engl J Med. 2009;361:496–509.
Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1616–1626.
Youn SW, Tsai TF, Theng C, et al. The MARCOPOLO study of ustekinumab utilization and efficacy in a real-world setting: treatment of patients with plaque psoriasis in asia-pacific countries. Ann Dermatol. 2016;28:222–231.
Youn SW, Yu DY, Kim BS, et al. Clinical outcomes in adult patients with plaque psoriasis treated with ustekinumab under real-world practice in Korea: a prospective, observational, multi-center, postmarketing surveillance study. J Dermatol. 2021;48:778–785.
Carrera CG, Dapavo P, Malagoli P, et al. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis. J Dermatolog Treat. 2018;29:481–486.
Galluzzo M, D'Adamio S, Silvaggio D, et al. Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. Expert Opin Biol Ther. 2020;20:95–104.
Kim BR, Kim M, Yang S, et al. Persistent expression of interleukin-17 and downstream effector cytokines in recalcitrant psoriatic lesions after ustekinumab treatment. J Dermatol. 2021;48:876–882.
Honda H, Umezawa Y, Kikuchi S, et al. Switching of biologics in psoriasis: reasons and results. J Dermatol. 2017;44:1015–1019.
Cozzani E, Wei Y, Burlando M, et al. Serial biologic therapies in psoriasis patients: a 12-year, single-center, retrospective observational study. J Am Acad Dermatol. 2020;82:37–44.
Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27:1535–1545.
Kim SA, Choi JW, Kim BR, et al. Correlation between histopathologic findings of psoriasis determined using quantitative computer-aided analysis and elements of the Psoriasis Area and Severity Index. J Am Acad Dermatol. 2015;73:325–326.
Schön MP, Erpenbeck L. The interleukin-23/interleukin-17 Axis links adaptive and innate immunity in psoriasis. Front Immunol. 2018;9:1323.
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945–1960.
Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol. 2009;90:232–248.
Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140:645–653.
Coimbra S, Figueiredo A, Castro E, et al. The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol. 2012;51:389–395.
Gao Y, Bian Z, Xue W, et al. Human IL-23r cytokine-binding homology region-fc fusion protein ameliorates psoriasis via the decrease of systemic Th17 and ILC3 cell responses. Int J Mol Sci. 2019;20:4170.
Reddy M, Torres G, McCormick T, et al. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J Dermatol. 2010;37:413–425.
Jack C, Mashiko S, Arbour N, et al. Persistence of interleukin (IL)-17A+ T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy. Br J Dermatol. 2017;177:267–270.
Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101:2620–2627.
Schüler R, Brand A, Klebow S, et al. Antagonization of IL-17a attenuates skin inflammation and vascular dysfunction in mouse models of psoriasis. J Invest Dermatol. 2019;139:638–647.
Bagel J, Zapata J, Nelson E. A prospective, open-label study evaluating adjunctive calcipotriene 0.005%/betamethasone dipropionate 0.064% foam in psoriasis patients with inadequate response to biologic therapy. J Drugs Dermatol. 2018;17:845–850.
Wolf P, Weger W, Legat FJ, et al. Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial. Br J Dermatol. 2012;166:147–153.